NASDAQ:ADAP

Adaptimmune Therapeutics Earning Date

USA |NASDAQ |USD

ADAP Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 3, 2021 Sep 2021 $-0.26 $-0.24 $-0.24
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 3, 2021 Sep 2021 $1.37M $3.10M $1.19M

Adaptimmune Therapeutics's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.

ADAP Earnings Date & History Chart

ADAP Earnings & Revenue Forecast

ADAP Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 5 $-0.26 $-0.28 $-0.25
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 5 $-0.98 $-1.03 $-0.81
Dec 2022 6 $-1.00 $-1.15 $-0.80

ADAP Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 1 / 0 $-0.27 $-0.25 $-0.25
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 2 / 0 $-1.00 $-0.98 $-0.98
Dec 2022 1 / 0 $-1.04 $-1.01 $-1.01

ADAP Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 7 $2.01M $0.00 $8.70M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 6 $5.21M $3.53M $8.50M
Dec 2022 8 $15.30M $0.00 $41.50M

ADAP Earnings Date & Revenue History

ADAP Earnings History

|
Show More
Show More

ADAP Revenue History

|
Show More
Show More

Adaptimmune Therapeutics Next Earnings Date & Report

ADAP Next Earnings Date & Report Preview: Sep 2021 (FQ)

ADAP's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 4 analysts, the average EPS estimation for Adaptimmune Therapeutics's next quarterly earnings is $-0.26, with a low EPS estimation of $-0.27, and a high estimation of $-0.26.

Over the last 1 month, EPS estimates have seen 1 upward revisions and 0 downward. The EPS 1 month trend is $-0.27, the last 2 month trend is $-0.25, and the 3 month trend is $-0.25.

Based on 8 analysts, the average revenue estimation is $1.37M, with a low revenue estimation of $0.00, and a high estimation of $4.50M.

Adaptimmune Therapeutics Previous Earnings Dates & Reports

ADAP Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Adaptimmune Therapeutics's previous earnings date was Aug 9, 2021 for its fiscal quarter ended Jun 30, 2021.

ADAP's earnings per share (EPS) was $-0.24, beating the consensus analysts forecast of $-0.24 by 1.64%.

The EPS was higher than the previous fiscal quarter (Mar 2021) by 0.00%, and higher than the same period a year before (Jun 2020) by 0.00%.

Revenues were $3.10M, better than the forecast of $3.10M by 0.00%, up by 613.13% from the previous quarter , and up by 516.53% from the same period last year.

The company reported a net income of $-38.99M.

Free cash flow for the quarter was $-80.92M , compared to $-47.83M last quarter and $-25.44M a year before.

ADAP ended the quarter with $22.64M in total debt, a decrease of -0.43% compared to the previous quarter, and a decrease of -2.84% compared to the same quarter a year before.

ADAP Previous Earnings Date & Report Recap: Dec 2020 (FY)

Adaptimmune Therapeutics's previous annual earnings date was Feb 25, 2021 for its fiscal year ended Dec 31, 2020.

ADAP's earnings per share (EPS) was $-0.96, missing the consensus analysts forecast of $-0.90 by 6.67% , and higher than the previous year's EPS (Dec 2019) by -27.27%.

Revenues were $3.96M, better than the forecast of $3.29M by 20.30%, and up by 252.76% from previous year's revenue.

The company reported a net income of $-130.09M.

Adaptimmune Therapeutics reported a free cash flow of $-56.50M for its fiscal year, compared to $-115.58M a year ago.

The company ended the fiscal year with $23.71M in total debt, a decrease of -6.87% compared to the previous year.